Outlook Therapeutics (NASDAQ:OTLK)

Outlook Therapeutics (NASDAQ:OTLK)


Share Price
$ 2.02
Change
0.01 (0.50 %)
Market Cap
$44.64 m
Proactive Investors - Run By Investors For Investors

Outlook Therapeutics

Outlook Therapeutics is a late clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a complex, technically challenging and commercially attractive monoclonal antibody, or mAb, for various ophthalmic indications.

Our goal is to launch ONS-5010 as the first, and only, approved bevacizumab in the United States, Europe, Japan and other markets for the...

EPIC: OTLK
Market: NASDAQ:OTLK
52-week High/Low: $10.880 / $0.850
Sector: Pharma & Biotech
Market Cap: $44.64 m
Website: outlooktherapeutics.com
col 3
col 4
col 5
col 6

Outlook Therapeutics Timeline

Video RSS

Videos

VIEW ALL VIDEOS

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use